{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:30:18Z","timestamp":1787913018297,"version":"build-2784847793"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-028"],"award-info":[{"award-number":["2022-PUMCH-C-028"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-044"],"award-info":[{"award-number":["2022-PUMCH-C-044"]}]},{"name":"CAMS Innovation Fund for Medical Sciences (CIFMS) of China","award":["2021-I2MC&T-B-002"],"award-info":[{"award-number":["2021-I2MC&T-B-002"]}]},{"name":"CAMS Innovation Fund for Medical Sciences (CIFMS) of China","award":["2017-I2M-1-001"],"award-info":[{"award-number":["2017-I2M-1-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02398-z","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:01:41Z","timestamp":1717570901000},"page":"3039-3048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas\/paragangliomas"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-3744","authenticated-orcid":false,"given":"Y.","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-7540","authenticated-orcid":false,"given":"A.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"6","key":"2398_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline [J]. J Clin Endocrinol Metab 99(6):1915\u20131942","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2398_CR2","doi-asserted-by":"publisher","first-page":"e1937","DOI":"10.1210\/clinem\/dgaa982","volume":"106","author":"D Granberg","year":"2021","unstructured":"Granberg D, Juhlin CC, Falhammar H (2021) Metastatic pheochromocytomas and abdominal paragangliomas [J]. J Clin Endocrinol Metab 106(5):e1937\u2013e1952","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2398_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Asa SL, Gill AJ et al (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas [J]. Endocr Pathol 33(1):90\u2013114","journal-title":"Endocr Pathol"},{"issue":"10","key":"2398_CR4","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot S, Leboulleux S, Amar L et al (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma [J]. J Clin Endocrinol Metab 98(10):4006\u20134012","journal-title":"J Clin Endocrinol Metab"},{"key":"2398_CR5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac657","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Cui Y, Zhang D et al (2022) Efficacy and safety of tyrosine kinase inhibitors in patients with metastatic pheochromocytomas\/paragangliomas: a systematic review and meta-analysis [J]. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgac657","journal-title":"J Clin Endocrinol Metab"},{"key":"2398_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fendo.2020.00061","volume":"11","author":"A Tong","year":"2020","unstructured":"Tong A, Li M, Cui Y et al (2020) Temozolomide Is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma-case report and review of the literature [J]. Front Endocrinol (Lausanne) 11:61","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2398_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB et al (2021) Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw 19(7):839\u201368","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2398_CR8","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY et al (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma [J]. Int J Cancer 135(11):2711\u20132720","journal-title":"Int J Cancer"},{"issue":"9","key":"2398_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/ERC-21-0392","volume":"29","author":"K Perez","year":"2022","unstructured":"Perez K, Jacene H, Hornick JL et al (2022) SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma [J]. Endocr Relat Cancer 29(9):533\u2013544","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2398_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noy132","volume":"21","author":"A Mansouri","year":"2019","unstructured":"Mansouri A, Hachem LD, Mansouri S et al (2019) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges [J]. Neuro Oncol 21(2):167\u2013178","journal-title":"Neuro Oncol"},{"key":"2398_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S et al (2016) RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group [J]. Eur J Cancer 62:138\u201345","journal-title":"Eur J Cancer"},{"issue":"2","key":"2398_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"MA Lodge","year":"2016","unstructured":"Lodge MA, Wahl RL (2016) Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0 [J]. Radiology 280(2):576\u201384","journal-title":"Radiology"},{"issue":"4","key":"2398_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","volume":"77","author":"A Thomas","year":"2017","unstructured":"Thomas A, Tanaka M, Trepel J et al (2017) Temozolomide in the era of precision medicine [J]. Cancer Res 77(4):823\u2013826","journal-title":"Cancer Res"},{"issue":"5","key":"2398_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M, Pongor L, Su YT et al (2020) MGMT Status as a clinical biomarker in glioblastoma [J]. Trends Cancer 6(5):380\u2013391","journal-title":"Trends Cancer"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02398-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02398-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02398-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:16:22Z","timestamp":1731046582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02398-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02398-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"16 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}